Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Assets (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Current Assets for 6 consecutive years, with $30.3 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 40.45% to $30.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.3 million through Dec 2025, down 40.45% year-over-year, with the annual reading at $30.3 million for FY2025, 40.45% down from the prior year.
  • Current Assets hit $30.3 million in Q4 2025 for Bolt Biotherapeutics, down from $35.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $271.2 million in Q1 2021 to a low of $30.3 million in Q4 2025.
  • Historically, Current Assets has averaged $128.8 million across 5 years, with a median of $128.1 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 645.87% in 2021 and later plummeted 55.28% in 2025.
  • Year by year, Current Assets stood at $189.2 million in 2021, then fell by 8.68% to $172.7 million in 2022, then tumbled by 38.81% to $105.7 million in 2023, then crashed by 51.93% to $50.8 million in 2024, then plummeted by 40.45% to $30.3 million in 2025.
  • Business Quant data shows Current Assets for BOLT at $30.3 million in Q4 2025, $35.6 million in Q3 2025, and $38.3 million in Q2 2025.